Richard Pratley, MD
Endocrinology, Diabetes & Metabolism · Orlando, FLNPI 1194837476
Payments from drug & device makers
Across 1,365 payments — averaging $6745.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$5.7M
- Boehringer Ingelheim International GmbH$2.2M
- Novo Nordisk AS$384K
- Novo Nordisk$192K
- Boehringer Ingelheim Pharma GmbH & Co.kg$135K
- AstraZeneca$99K
- plus $456K from 22 others
Across 70 payments — averaging $1229.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$71K
- Novo Nordisk AS$10K
- Sanofi-aventis U.S. LLC$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $5,734,334 |
| Boehringer Ingelheim International GmbH | 560 | $2,207,852 |
| Novo Nordisk AS | 348 | $384,278 |
| Novo Nordisk | 126 | $192,061 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 41 | $135,334 |
| AstraZeneca | 2 | $98,739 |
| Lilly USA, LLC | 59 | $73,814 |
| Merck | 34 | $63,763 |
| Dompe Farmaceutici S.p.a. | 11 | $54,421 |
| Lexicon Pharmaceuticals, Inc. | 12 | $46,182 |
| Corcept Therapeutics | 43 | $40,683 |
| Janssen Research & Development, LLC | 8 | $34,116 |
| Sanofi | 3 | $33,802 |
| Boehringer Ingelheim | 29 | $28,755 |
| Pfizer | 21 | $24,529 |
| Amgen | 6 | $12,867 |
| Bayer | 25 | $12,817 |
| AbbVie | 7 | $11,620 |
| F. Hoffmann-la Roche AG | 7 | $10,289 |
| Sanofi US Services Inc. | 4 | $2,655 |
| Abbott | 4 | $2,324 |
| Medtronic | 3 | $2,192 |
| Astrazeneca AB | 1 | $450 |
| Zealand Pharma A/s | 1 | $82 |
| Amarin Pharma, Inc. | 1 | $59 |
| Myocardial Solutions, Inc. | 1 | $48 |
| Mannkind Corporation | 1 | $31 |
| Insulet Corporation | 2 | $23 |
How this compares
$9,208,121 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Orlando
- Steven SmithOrlando$7.9M
- Tina ThethiOrlando$3.8M
- Damon TantonOrlando$1.2M
- Hanford YauOrlando$489K
- Jose MandryOcoee$9.1M
- Barry HorowitzWest Palm Beach$7.1M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
- Mae Sheikh AliJacksonville$2.9M
- James MageeJacksonville$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.